Tumor LAG‐3 and NY‐ESO‐1 expression predict durable clinical benefits of immune checkpoint inhibitors in advanced non‐small cell lung cancer

BACKGROUND: Immune checkpoint inhibitors (ICIs) are an established treatment for non‐small cell lung cancer (NSCLC) that have demonstrated durable clinical benefits (DCBs). Previous studies have suggested NY‐ESO‐1 and LAG‐3 to be surrogate markers of ICI responses in NSCLC; therefore, we explored th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Thorac Cancer
Asıl Yazarlar: Jung, Eun Hee, Jang, Hee Ryeong, Kim, Se Hyun, Suh, Koung Jin, Kim, Yu Jung, Lee, Ju‐Hyun, Chung, Jin‐Haeng, Kim, Miso, Keam, Bhumsuk, Kim, Tae Min, Kim, Dong‐Wan, Heo, Dae Seog, Lee, Jong Seok
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons Australia, Ltd 2021
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7919166/
https://ncbi.nlm.nih.gov/pubmed/33458968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13834
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller